

The evidence you cant ignore.

Wilate now approved for prophylaxis in Canada

WIL-31 study confirms Wilate[®] prophylaxis in reducing bleeding in VWD patients

The WIL-31 study is a significant prospective prophylaxis study on von Willebrand disease (VWD), the largest of its kind. It uniquely includes a prospective on-demand run-in as an intra-individual comparator. The study demonstrates that prophylaxis with Wilate[®], a von Willebrand factor/factor VIII (VWF/FVIII) concentrate, is highly effective in reducing bleeding rates in both children and adults with all types of VWD compared to previous on-demand treatment.

Octapharma announced these results, which were published in Blood Advances by Sidonio RF Jr et al., under the title "Von Willebrand factor/factor VIII concentrate (Wilate[®]) prophylaxis in children and adults with von Willebrand disease."

The study included a diverse patient population, covering young children and adults of both genders and all types of VWD.

The findings support the use of VWF prophylaxis and have led to the addition of Wilate[®] prophylaxis as a therapeutic indication for VWD in the US, thereby increasing access for the patient population.

Heavy menstrual bleeding (HMB) and VWD

- 📌 HMB is excessive menstrual blood loss that interferes with a woman's physical, emotional, social and material QoL¹
- 📌 HMB is the most common symptom observed in women with VWD²

In women with VWD, HMB is associated with significant morbidity³

HMB occurs in



of women with VWD³

QoL: quality of life; VWD: von Willebrand disease.

1. Heavy menstrual bleeding. Clinical guideline 88. London National Institute for Health and Clinical Excellence; May 2021;

2. Weyand AC et al. *Res Pract Thromb Haemost* 2021; 5:51-4; 3. Ragni MV et al. *Haemophilia* 2016; 22:397-402.

For full prescribing information, please refer to the product monograph.

Burden of HMB in VWD



~9-fold more frequent hospitalisation than women with HMB without VWD¹



Iron deficiency and anaemia iron deficiency²



11% of women with moderate/severe VWD required a **blood transfusion** at least once due to HMB³



Impact on health-related **quality of life**⁴



Interference with social activities, school and work⁵

1. Holm E et al. *Haemophilia* 2018; 24:628-33; 2. Munro MG et al. *Am J Obstet Gynecol* 2023; 229:1-9.; 3. de Wee EM et al. *Thromb Haemost* 2011; 106:885-92; 4. Rae C et al. *Haemophilia* 2013; 19:385-91; 5. Sanigorska A et al. *Res Pract Thromb Haemost* 2022; 6:e12652.

For full prescribing information, please refer to the product monograph.

HMB effects approximately one in four women¹ and is caused by a variety of disorders

International Federation of Gynecology and Obstetrics classification for the causes of abnormal uterine bleeding, including HMB^{2,3}




PCOS: Polycystic ovary syndrome;

1. Pašalić E et al. *Pathol Res Pract* 2023; 251:154847; 2. Whitaker L and Critchley HOD. *Best Pract Res Clin Obstet Gynaecol* 2016; 34:54-65;

3. American College of Obstetricians and Gynecologists. Heavy Menstrual Bleeding (2022). <https://www.acog.org/womens-health/faqs/heavy-menstrual-bleeding> (accessed Jan 2024)

For full prescribing information, please refer to the product monograph.

WIL-31: HMB reduced in all women of childbearing age during wilate[®] prophylaxis



No additional treatment or hospitalisation was required for any HMB during prophylaxis




* No cases of HMB recorded in either study.




Octapharma, data on file.

For full prescribing information, please refer to the product monograph.

WIL-31: wilate[®] prophylaxis reduced HMB severity


PBAC and scoring system

Pads		
Light  (1 pt each)	Medium  (5 pts each)	Heavy  (20 pts each)

Tampons		
Light  (1 pt each)	Medium  (5 pts each)	Heavy  (10 pts each)

Clots		Flooding
5 cent size (1 pt each)	50 cent size (5 pts each)	1 pt each episode

Mean PBAC scores for individual patients*¹ (n = 4)



*Only patients with PBAC for both WIL-29 and WIL-31 shown. [†]PBAC scores ≥185 correlates with HMB (>80 mL of menstrual blood loss).

PBAC: Pictorial blood assessment chart. Octapharma, data on file.

For full prescribing information, please refer to the product monograph.